By Matt Grossman
Johnson & Johnson's second-quarter revenue grew by 27% as rising sales of its medical devices, drugs and consumer-health products helped grow the company's profit.
The New Brunswick, N.J.-based pharmaceutical company logged second-quarter earnings of $2.35 a share, up from $1.36 a share in the same three-month period a year earlier. Net earnings rose to $6.28 billion, up from $3.63 billion in 2020's second quarter.
Excluding one-time items, J&J's adjusted earnings were $2.48 a share. Analysts surveyed by FactSet had forecast adjusted earnings of $2.29 a share.
Sales climbed to $23.31 billion, from $18.34 billion 12 months earlier. Analysts were anticipating revenue of $22.49 billion.
Pharmaceutical sales rose 17% to $12.6 billion. Consumer-health sales rose 13% to $3.74 billion. Medical-devices sales were up 63% to $6.98 billion.
World-wide sales of the J&J Covid-19 vaccine in the quarter were $164 million.
Write to Matt Grossman at firstname.lastname@example.org
(END) Dow Jones Newswires
July 21, 2021 07:01 ET (11:01 GMT)Copyright (c) 2021 Dow Jones & Company, Inc.